3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
25
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Biochemically Recurrent Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
fludarabine
26
Cyclophosphamide
21
Azacitidine
20
venetoclax
18
Specimen Handling
18
fludarabine phosphate
17
Whole-Body Irradiation
14
Mycophenolic Acid
14
Melphalan
14
Busulfan
14
Biopsy
14
Tacrolimus
12
Cytarabine
12
Granulocyte Colony-Stimulating Factor
10
decitabine and cedazuridine drug combination
9
Decitabine
9
Stem Cell Transplantation
8
Sirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Injections
8
Filgrastim
8
Cyclosporine
8
Thiotepa
6
ruxolitinib
5
X-Rays
5
Idarubicin
5
CPX-351
5
Magnetic Resonance Spectroscopy
4
Cladribine
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
darolutamide
×
90 days
×
Clear all
No trials found.